논문검색
Author Atsushi Horiike and Nagahiro Saijo
Place of duty Division of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
Title Treatment of Small Cell Lung Cancer
Publicationinfo Cancer Research and Treatment 2003 Jun; 035(03): 177-180.
Key_word Small cell lung cancer, Chemotherapy, Radiation therapy, Cisplatin, Etoposide, Irinotecan
Full-Text
Abstract Among patients with lung cancer, approximately 15% have small cell lung cancer (SCLC), SCLC is usually staged as either limited and extensive. Extensive-stage SCLC is treated primarily with chemotherapy. A recent Japanese randomized trial compared cisplatin and irinotecan (IP) with cisplatin and etoposide (EP). Patients in the IP arm did significantly better than patients in the EP arm. In the IP arm, the response rate was 84%, and the median overall survival period was 12.8 months. Limited- stage SCLC is usually treated with concurrent chemothe- rapy and accelerated radiation therapy, and approximately 20% of patients are cured. Future research should focus on optimizing chemotherapy regimens and radiation therapy schedules. The role of molecular targeted drugs in the treatment of SCLC must also be evaluated. (Cancer Research and Treatment 2003;35:177 180)